October 15, 2020

EMA launches public consultation on the draft Guideline concerning registry-based studies

Last September, the EMA published its draft Guideline on registry-based studies (“Guideline”). This draft Guideline is currently open for public consultation: stakeholders may post comments until December 31, 2020.

A registry-based study is an investigation of a research question using data from a new or existing patient registry for patient recruitment and data collection. Patient registries are data collection systems for data on a group of people with a particular disease or condition; a registry is established for a specific purpose and used to conduct a registry-based study. Registries contain a lot of information on diseases, patients, standards of care, use of medicines, devices, and results of care and have already been the subject of initiatives carried out by the EMA since September 2015 (with regard to the initiative for patient registries launched in November 2018, please also refer to our article “Registri di malattia dei pazienti: potenzialità di utilizzo a fini regolatori”).

A registry-based study may be a clinical study or a non-interventional study. Studies based on patient registries provide real evidence to complement the results obtained from clinical trials and pre-clinical studies and to improve knowledge about the risks and benefits associated with the daily use of medicines.

The Guideline provides regulatory requirements and recommendations on key methodological aspects for the use of patient registries by marketing authorization applicants and holders in order to carry out studies, including the following:

  • planning a registry-based study requires identifying one suitable registry or multiple suitable registries and obtaining agreement to participate from each registry, as well as from each individual center if no central registry coordination exists, potentially selecting a third party to be involved in the study and set up a database, and establishing a data extraction process and quality control practices (par. 3.3 of the Guideline);
  • the study protocol should describe how the registry infrastructure and population will be used to address the scientific question at stake, how the study will be conducted, and how the validity of the results will be ensured (par. 3.4 of the Guideline).

The final version of Guideline will reflect stakeholders’ comments and will be published in 2021.

< Back to blog
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the life sciences and healthcare industry.
...
Read more
Our highly-ranked team of professionals will provide newsinsights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and venture capital transactions.

Close
June 6, 2022
The National Coordination Centre for Ethics Committees published new draft agreements for conducting clinical trials on drugs and medical devices
April 27, 2022
EU Medical Device Coordination Group (MDCG) approves “Guidance” on the borderline between medical devices and medicinal products in order to support the uniform application of Regulation...
April 5, 2022
Electronic prescriptions: the current modalities of transmission from doctors to patients and from patients to pharmacies are extended until 31st December 2022
March 24, 2022
EU Medical Device Coordination Group (MDCG) approves “Guidance” on appropriate surveillance of devices covered by certificates according to the MD Directives, under the transitional prov...
March 21, 2022
Published Decree of Health Ministry identifying the ethics committees of national significance for clinical trials of medicinal products and medical devices
Search by...
Search
Follow us on
Follow us on